The purpose of this study is to evaluate activity and toxicity of the combination of carboplatin and liposomal doxorubicin as first-line chemotherapy of patients with advanced or recurrent endometrial carcinoma.

Treatment is planned with carboplatin AUC 5 given IV on day 1 and liposomal doxorubicin 40 mg/m2 given IV on day 1, with treatment repeated every 28 days. Delays in treatment administration and dose reductions have been planned according to toxicity.

Inclusion Criteria:

• Cytologic / histologic diagnosis of endometrial carcinoma
• Indication for chemotherapy
• Age 75 years or less
• Life expectancy of at least 3 months
• Measurable disease > 1 cm

Exclusion Criteria:

• Previous or concomitant malignant neoplasia (not including basocellular or spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided they are being adequately treated)
• Performance status (ECOG) > 2
• Previous chemotherapy treatment
• Heart disease (heart failure, myocardial heart attack within 6 months prior to randomization, atrioventricular block of any degree, serious arrhythmia)
• Leukocytes < 4000/mm3, platelets < 100000/mm3
• Impaired renal function (creatinine > o = 1.25 times the upper normal limit) or liver function (SGOT or SGPT > o = 1.25 times the upper normal limit)
• Present or suspected hemorrhagic syndromes
• Uncooperative and/or unreliable patients
• Patient's inability to access the center
• Refusal of informed consent